Liafensine
Chemical compound / From Wikipedia, the free encyclopedia
Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder.[1][2] Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse.[1] Another clinical trial of liafensine began in 2022.[3]
Quick Facts Clinical data, Routes ofadministration ...
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H22N4 |
Molar mass | 366.468 g·mol−1 |
3D model (JSmol) | |
| |
|
Close